332 related articles for article (PubMed ID: 33979451)
1. Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder.
Devinsky O; King L; Schwartz D; Conway E; Price D
Epilepsia; 2021 Jul; 62(7):e98-e102. PubMed ID: 33979451
[TBL] [Abstract][Full Text] [Related]
2. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial.
Lagae L; Sullivan J; Knupp K; Laux L; Polster T; Nikanorova M; Devinsky O; Cross JH; Guerrini R; Talwar D; Miller I; Farfel G; Galer BS; Gammaitoni A; Mistry A; Morrison G; Lock M; Agarwal A; Lai WW; Ceulemans B;
Lancet; 2019 Dec; 394(10216):2243-2254. PubMed ID: 31862249
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: Compassionate use program in Germany.
Strzelczyk A; Pringsheim M; Mayer T; Polster T; Klotz KA; Muhle H; Alber M; Trollmann R; Spors H; Kluger G; Kurlemann G; Schubert-Bast S
Epilepsia; 2021 Oct; 62(10):2518-2527. PubMed ID: 34378197
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of fenfluramine in patients with Dravet syndrome: A meta-analysis.
Zhang L; Li W; Wang C
Acta Neurol Scand; 2021 Apr; 143(4):339-348. PubMed ID: 33336426
[TBL] [Abstract][Full Text] [Related]
5. Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial.
Nabbout R; Mistry A; Zuberi S; Villeneuve N; Gil-Nagel A; Sanchez-Carpintero R; Stephani U; Laux L; Wirrell E; Knupp K; Chiron C; Farfel G; Galer BS; Morrison G; Lock M; Agarwal A; Auvin S;
JAMA Neurol; 2020 Mar; 77(3):300-308. PubMed ID: 31790543
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A real-world study.
Specchio N; Pietrafusa N; Doccini V; Trivisano M; Darra F; Ragona F; Cossu A; Spolverato S; Battaglia D; Quintiliani M; Luigia Gambardella M; Rosati A; Mei D; Granata T; Dalla Bernardina B; Vigevano F; Guerrini R
Epilepsia; 2020 Nov; 61(11):2405-2414. PubMed ID: 32945537
[TBL] [Abstract][Full Text] [Related]
7. Low-dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients.
Schoonjans A; Paelinck BP; Marchau F; Gunning B; Gammaitoni A; Galer BS; Lagae L; Ceulemans B
Eur J Neurol; 2017 Feb; 24(2):309-314. PubMed ID: 27790834
[TBL] [Abstract][Full Text] [Related]
8. Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes.
Frampton JE
Drugs; 2023 Jul; 83(10):923-934. PubMed ID: 37316680
[TBL] [Abstract][Full Text] [Related]
9. Fenfluramine significantly reduces day-to-day seizure burden by increasing number of seizure-free days and time between seizures in patients with Dravet syndrome: A time-to-event analysis.
Sullivan J; Specchio N; Devinsky O; Auvin S; Perry MS; Strzelczyk A; Gil-Nagel A; Dai D; Galer BS; Gammaitoni AR
Epilepsia; 2022 Jan; 63(1):130-138. PubMed ID: 34676542
[TBL] [Abstract][Full Text] [Related]
10. Fenfluramine for treatment-resistant epilepsy in Dravet syndrome and other genetically mediated epilepsies.
Sullivan J; Simmons R
Drugs Today (Barc); 2021 Jul; 57(7):449-454. PubMed ID: 34268532
[TBL] [Abstract][Full Text] [Related]
11. Improved everyday executive functioning following profound reduction in seizure frequency with fenfluramine: Analysis from a phase 3 long-term extension study in children/young adults with Dravet syndrome.
Bishop KI; Isquith PK; Gioia GA; Gammaitoni AR; Farfel G; Galer BS; Nabbout R; Wirrell EC; Polster T; Sullivan J
Epilepsy Behav; 2021 Aug; 121(Pt A):108024. PubMed ID: 34023810
[TBL] [Abstract][Full Text] [Related]
12. Effect of fenfluramine on seizures and comorbidities in SCN8A-developmental and epileptic encephalopathy: A case series.
Aledo-Serrano Á; Cabal-Paz B; Gardella E; Gómez-Porro P; Martínez-Múgica O; Beltrán-Corbellini A; Toledano R; García-Morales I; Gil-Nagel A
Epilepsia Open; 2022 Sep; 7(3):525-531. PubMed ID: 35802036
[TBL] [Abstract][Full Text] [Related]
13. A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication.
Strzelczyk A; Schubert-Bast S
CNS Drugs; 2022 Mar; 36(3):217-237. PubMed ID: 35156171
[TBL] [Abstract][Full Text] [Related]
14. The contribution of fenfluramine to the treatment of Dravet syndrome in Spain through Multi-Criteria Decision Analysis.
Gil-Nagel A; Falip M; Sánchez-Carpintero R; Abad-Sazatornil MR; Poveda JL; Aibar JÁ; Cardenal-Muñoz E; Aras LM; Sánchez R; Sancho-López A; Trillo-Mata JL; Torrejón M; Gil A
Epilepsy Behav; 2022 Jul; 132():108711. PubMed ID: 35588562
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapy for Dravet Syndrome: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
Lattanzi S; Trinka E; Russo E; Del Giovane C; Matricardi S; Meletti S; Striano P; Damavandi PT; Silvestrini M; Brigo F
Drugs; 2023 Oct; 83(15):1409-1424. PubMed ID: 37695433
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of fenfluramine in patients with Dravet syndrome: A systematic review and meta-analysis.
Sharawat IK; Panda PK; Kasinathan A; Panda P; Dawman L; Joshi K
Seizure; 2021 Feb; 85():119-126. PubMed ID: 33461030
[TBL] [Abstract][Full Text] [Related]
17. Vagus nerve stimulation for the treatment of refractory epilepsy in the CDKL5 Deficiency Disorder.
Lim Z; Wong K; Downs J; Bebbington K; Demarest S; Leonard H
Epilepsy Res; 2018 Oct; 146():36-40. PubMed ID: 30071384
[TBL] [Abstract][Full Text] [Related]
18. Failure to use new breakthrough treatments for epilepsy.
Klein P; Krauss GL; Steinhoff BJ; Devinsky O; Sperling MR
Epilepsia; 2023 Jun; 64(6):1458-1465. PubMed ID: 36855241
[TBL] [Abstract][Full Text] [Related]
19. CDKL5 deficiency disorder: Relationship between genotype, epilepsy, cortical visual impairment, and development.
Demarest ST; Olson HE; Moss A; Pestana-Knight E; Zhang X; Parikh S; Swanson LC; Riley KD; Bazin GA; Angione K; Niestroj LM; Lal D; Juarez-Colunga E; Benke TA
Epilepsia; 2019 Aug; 60(8):1733-1742. PubMed ID: 31313283
[TBL] [Abstract][Full Text] [Related]
20. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
